CHINA BD & STRATEGIC ACCESS
Access the Right Partners and Capital in China
China has become a key source of capital, licensing opportunities, and strategic partnerships for biotech companies. But accessing the right investors and partners requires more than interest, it requires the right relationships, positioning, and timing.
Many companies struggle to clearly answer:
- How do you access the right China-based investors and pharma partners?
- How do you position your program for licensing or partnership discussions?
- How do you navigate a different business and decision-making environment?
- How do you build trust and move conversations forward?
Without the right access and engagement strategy, opportunities in China are often missed or delayed.
The Biotech Challenges
- Limited Access to Investors and Partners
Many companies lack direct relationships with Chinese pharma companies, investors, and BD teams.
- Difficulty Securing Licensing Opportunities
Strong programs exist, but companies struggle to position their assets effectively for regional licensing or co-development deals.
- Misalignment with Local Expectations
What resonates with U.S. or global stakeholders often does not translate effectively to Chinese partners and investors.
- Complex Market and Decision Dynamics
The China biotech landscape operates differently, requiring local understanding of regulatory, commercial, and partnership processes.
- Trust and Relationship Barriers
Building credibility in China requires more than outreach – it requires aligned communication and trusted connections.
- Fragmented BD Efforts
Without a clear strategy, outreach efforts are inconsistent and fail to generate meaningful traction.
The Bowei Solutions
China BD Strategy & Positioning
We define how your program should be positioned for China -aligning scientific, commercial, and strategic narratives for local relevance.
Targeted Partner & Investor Identification
We identify and prioritize relevant Chinese pharma companies, biotech partners, and investors aligned with your asset and stage.
Access to Investors & Pharma Partners
We leverage established relationships to facilitate targeted introductions to relevant investors and BD teams.
Cross-Border Engagement Support
We support early-stage discussions to ensure alignment, build trust, and maintain momentum across conversations.
Case Study
The Situation
A U.S.-based immunology biotech developing a Phase II asset was exploring partnership opportunities in China but lacked direct access to relevant pharma partners and investors.
Key challenges included:
- limited visibility among Chinese BD teams
- unclear positioning for licensing discussions
- difficulty identifying the right strategic partners
Our Approach
We supported the company in developing both strategy and access.
This included:
- refining positioning to align with China market expectations
- identifying and prioritizing relevant Chinese pharma partners and investors
- facilitating targeted introductions to BD teams and decision-makers
- supporting early-stage discussions to build alignment and trust
The Outcome
With improved positioning and direct access, the company accelerated its China BD efforts.
This led to:
- increased engagement with targeted Chinese pharma companies and investors
- stronger inbound interest following introductions
- more focused and productive licensing and partnership discussions
- accelerated momentum in cross-border opportunities
Access Capital, Partners, and Opportunities in China
China represents a major opportunity for capital, licensing, and strategic partnerships but only with the right access.
We help you connect with the right investors and partners, position your program effectively, and move opportunities forward.